

## Central Lancashire Online Knowledge (CLOK)

Title	Evidence for the Quercetin Binding Site of Glycogen Phosphorylase as a Target for Liver-Isoform-Selective Inhibitors against Glioblastoma: Investigation of Flavanols Epigallocatechin Gallate and Epigallocatechin
Type	Article
URL	<a href="https://clock.uclan.ac.uk/id/eprint/53472/">https://clock.uclan.ac.uk/id/eprint/53472/</a>
DOI	<a href="https://doi.org/10.1021/acs.jafc.4c06920">https://doi.org/10.1021/acs.jafc.4c06920</a>
Date	2024
Citation	Alexopoulos, Serafeim, McGawley, Megan, Mathews, Roshini Mariam, Papakostopoulou, Souzana, Koulas, Symeon, Leonidas, Demetres D., Zwain, Tamara, Hayes, Joseph and Skamnaki, Vasiliki (2024) Evidence for the Quercetin Binding Site of Glycogen Phosphorylase as a Target for Liver-Isoform-Selective Inhibitors against Glioblastoma: Investigation of Flavanols Epigallocatechin Gallate and Epigallocatechin. <i>Journal of Agricultural and Food Chemistry</i> , 72 (43). pp. 24070-24081. ISSN 0021-8561
Creators	Alexopoulos, Serafeim, McGawley, Megan, Mathews, Roshini Mariam, Papakostopoulou, Souzana, Koulas, Symeon, Leonidas, Demetres D., Zwain, Tamara, Hayes, Joseph and Skamnaki, Vasiliki

It is advisable to refer to the publisher's version if you intend to cite from the work.  
<https://doi.org/10.1021/acs.jafc.4c06920>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

# Evidence for the Quercetin Binding Site of Glycogen Phosphorylase as a Target for Liver-Isoform-Selective Inhibitors against Glioblastoma: Investigation of Flavanols Epigallocatechin Gallate and Epigallocatechin

Serafeim Alexopoulos, Megan McGawley, Roshini Mathews, Souzana Papakostopoulou, Symeon Koulas, Demetres D. Leonidas, Tamara Zwain, Joseph M. Hayes, and Vasiliki Skamnaki\*



Cite This: <https://doi.org/10.1021/acs.jafc.4c06920>



Read Online

ACCESS |



Metrics & More



Article Recommendations



Supporting Information

**ABSTRACT:** Glycogen phosphorylase (GP) is the rate-determining enzyme in glycogenolysis, and its druggability has been extensively studied over the years for the development of therapeutics against type 2 diabetes (T2D) and, more recently, cancer. However, the conservation of binding sites between the liver and muscle isoforms makes the inhibitor selectivity challenging. Using a combination of kinetic, crystallographic, modeling, and cellular studies, we have probed the binding of dietary flavonoids epigallocatechin gallate (EGCG) and epigallocatechin (EGC) to GP isoforms. The structures of rmGPb-EGCG and rmGPb-EGC complexes were determined by X-ray crystallography, showing binding at the quercetin binding site (QBS) in agreement with kinetic studies that revealed both compounds as noncompetitive inhibitors of GP, with EGCG also causing a significant reduction in cell viability and migration of U87-MG glioblastoma cells. Interestingly, EGCG exhibits different binding modes to GP isoforms, revealing QBS as a promising site for GP targeting, offering new opportunities for the design of liver-selective GP inhibitors.

**KEYWORDS:** EGCG, flavanols, glioblastoma, glycogen phosphorylase, quercetin binding site

## INTRODUCTION

Inhibition of glycogen degradation (glycogenolysis) in the liver contributes to the control of glycemia and is a long-recognized therapeutic strategy against type 2 diabetes (T2D).<sup>1</sup> More recently, the role of glycogenolysis in cancer has been recognized, including glioblastoma (GBM).<sup>2,3</sup> Glycogenolysis occurs through a cascade of hormone-regulated enzyme reactions. Glycogen phosphorylase (GP; EC 2.4.1.1) is the enzyme that catalyzes the first step of glycogenolysis toward the production of glucose-1-phosphate. It is shown that the inhibition of GP is highly effective in reducing hepatic glucose output in rodent models of diabetes, rendering GP a promising molecular target toward the development of antihyperglycemic agents.<sup>4,5</sup> It was also demonstrated that depleting liver GP through silencing of the hepatic GP isoform gene, the liver isoform was associated with glycogen accumulation, reduced cancer cell proliferation, and corresponding induction of senescence.<sup>6</sup> A more recent study has additionally shown that liver GP is upregulated in GBM and that glycogen degradation inhibition sensitizes GBM cells to high-dose radiation.<sup>7</sup> It has also been shown that liver GP is highly expressed in gliomas and that this can be used as a predictive marker for poor prognosis.<sup>8</sup> Whether the use of GP inhibitors, rather than modulation of liver GP isoform expression, could be beneficial for the treatment of cancer is under investigation. On this basis, a combined direct study on GP inhibitor design for GBM was reported, with promising anticancer effects demonstrated for baicalein.<sup>9</sup> GP exists in 3 main tissue-specific isoforms in the liver, muscle, and brain. GP is an allosteric


enzyme according to the Wyman–Monod–Changeux model and, through effector binding, adopts two interconverting states, a low-activity (T) state and a high-activity (R) state. Its activation through phosphorylation (inactive form of GPb to active GPa) is hormonally controlled. GP has several ligand-binding sites that can be exploited for inhibitor binding. These include the active site and sites for the physiological effectors such as AMP (allosteric site) and the glycogen binding site (storage site), as well as a hydrophobic site where purine-based compounds such as caffeine bind (inhibitor site).<sup>10</sup>

Over the years, the remarkable “druggability” of GP has been revealed, as new binding sites have been identified by crystallographic studies. These include an indole-based compound binding site (new allosteric or drug site),<sup>11</sup> a benzimidazole site,<sup>12</sup> and, most recently, the quercetin binding site (QBS).<sup>13</sup> Kinetic and crystallographic studies<sup>14–18</sup> from our lab and others have revealed many potent inhibitors with  $K_i$  values in the order of nM toward GP. A number of these are natural compounds exhibiting a repertoire of different chemical scaffolds, including flavonoids, triterpenes, anthocyanins, and benzoic acid derivatives.<sup>19,20</sup> The majority of the discovered

**Received:** August 1, 2024

**Revised:** October 7, 2024

**Accepted:** October 8, 2024



**Figure 1.** Chemical structures of flavonols: (A) EGCG [(−)-epigallocatechin gallate and (B) EGC [(−)-epigallocatechin]. The rings of each compound are presented by letters (A, B, C, and D).

GP inhibitors bind at the catalytic site that has a similar architecture in all isoforms; hence, the discovery of selective inhibitors that target only the human liver GP and not the muscle one remains a major challenge. Dietary flavanols are associated with a plethora of beneficial health effects. Epigallocatechin gallate (EGCG) and epigallocatechin (EGC) are the major bioactive flavanols of green tea (*Camellia sinensis*) with antioxidant, chemopreventive, anti-inflammatory, and antidiabetic effects.<sup>21</sup> The structure of EGCG consists of four rings resulting from the esterification of EGC with gallic acid: the A and C rings constitute the benzopyran ring with a pyrogallol moiety at position 2, the B ring, with a gallate moiety at position 3, and the D ring (Figure 1).<sup>22</sup>

The substituents at positions 3', 4', and 5' of the B ring and 3', 4', and 5' of the D ring are hydroxyl groups. In an early study<sup>23</sup> by Jakobs et al., EGCG was shown to potently inhibit GP (IC<sub>50</sub> values for GP<sub>a</sub> and GP<sub>b</sub> of 7.7 and 33.9  $\mu$ M, respectively). Even though catechins are nonplanar molecules, catechin-3-gallates inhibit GP<sub>a</sub> activity to an extent similar to quercetin and luteolin. Back then, their inhibitory effect was conjectured to occur by binding at the inhibitor site due to the structural similarity with flavopiridol, a synthetic flavonoid derivative already known<sup>24</sup> to bind at the same site. In light of the later identification of a different binding site for quercetin, we hypothesized that EGCG may bind at the QBS, and in this work, we provide the experimental evidence to support this. Using a combination of docking, kinetics, and crystallographic studies, we have examined the binding modes of the flavanols EGCG and EGC to GP isoforms, while the anticancer potential of EGCG was further assessed against GBM through studies with U87-MG cells.

## MATERIALS AND METHODS

**Protein Purification.** Rabbit skeletal muscle glycogen phosphorylase b (rmGP<sub>b</sub>) was isolated and then purified using the modified Fisher and Krebs method, as described.<sup>25</sup> Human liver GP (hlGP) was expressed in *E. coli* and purified according to the protocol.<sup>14</sup> The phosphorylated forms rmGP<sub>a</sub> and hlGP<sub>a</sub> were produced by phosphorylation using the constitutively active kinase domain of glycogen phosphorylase kinase (PhK $\gamma$ trnc), as described.<sup>14,26</sup>

**Enzyme Assays. In Vitro GP Inhibition.** The activities of rmGP<sub>b</sub>, rmGP<sub>a</sub>, and hlGP<sub>a</sub> were measured in the direction of glycogen synthesis by monitoring the release of inorganic phosphate, as described.<sup>15</sup> rmGP<sub>b</sub> (3  $\mu$ g/mL), rmGP<sub>a</sub> (3  $\mu$ g/mL), and hlGP<sub>a</sub> (1  $\mu$ g/mL) were assayed in the presence of glycogen (0.2% w/v) and AMP (1 mM). The reaction buffer contained 30 mM imidazole/HCl buffer (pH 6.8), 60 mM KCl, 0.6 mM EDTA, and 0.6 mM DTT.

EGCG [(−)-epigallocatechin gallate] and EGC [(−)-epigallocatechin] were purchased by Extrasynthese (989-51-5/0981S and 970-74-1/0979S, respectively). In order to calculate the inhibition constant ( $K_i$ ) of EGCG with respect to GP, various concentrations of the inhibitor (0, 20, 40, 60, 80, 100  $\mu$ M with respect to rmGP<sub>b</sub> and 0, 20, 40, 60, 80, 100  $\mu$ M with respect to rmGP<sub>a</sub>) were assayed in various glucose-1-phosphate (G1P) concentrations (2, 3, 4, 6, 10 mM). Also, for the determination of the  $K_i$  of EGCG with respect to hlGP<sub>a</sub>, the inhibitor concentrations were 0, 20, 40, 60, and 80  $\mu$ M at various G1P concentrations (1, 2, 3, 4, and 6 mM). The inhibitory effect of EGCG in synergy with well-established<sup>27</sup> GP ligands was assessed through multiple inhibition studies. The activity of rmGP<sub>b</sub> was assayed in the presence of several concentrations of EGCG (0–100  $\mu$ M) and varying concentrations of (a) caffeine (0–0.7 mM), (b) glucose (0–12 mM), and (c) AMP (0–0.5 mM). The inhibition constant ( $K_i$ ) of EGC with respect to rmGP<sub>b</sub> was calculated at EGC concentrations (0, 40, 80, 180, 250, 350  $\mu$ M) and various G1P concentrations (2, 3, 4, 6, and 10 mM).

**Inhibition of GP Activity in HepG2 Cells.** HepG2 cells (1.5 million/dish) were grown in Dulbecco's modified Eagle's medium (DMEM), which was enriched with 25 mM glucose, 2 mM L-glutamine, 10% fetal bovine serum (FBS), and a penicillin/streptomycin antibiotic mixture. The cells were cultured at 37 °C in a 5% CO<sub>2</sub> incubator. Sixteen hours after seeding, the medium was replaced by a high-glucose DMEM supplemented with 10 mM dexamethasone and 100 nM insulin that lacked L-glutamine and FBS in order to trigger the glycogen synthesis pathway. The cells were incubated overnight in high-glucose medium and after they were incubated in the presence or absence of different concentrations of EGCG (60 and 100  $\mu$ M) and caffeine (200  $\mu$ M) for 3 h in a glucose-free DMEM without phenol red, FBS, and L-glutamine, with the addition of glucagon (100 nM), to activate glycogenolysis. The cells were lysed and sonicated (4 cycles  $\times$  1s, 35% amplitude) and centrifuged at 15,600 rcf for 15 min at 4 °C. The activity of GP<sub>a</sub> in cell lysates (supernatant) was measured by glycogen synthesis, as described.<sup>25</sup> The program GraFit<sup>28</sup> was used for kinetic data statistical analysis. The cell cytotoxicity during the incubation with EGCG was estimated using the 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay.<sup>29</sup>

**Glioblastoma Cellular Studies. Cell Viability.** Cell viability experiments were performed on the U87-MG GBM cell line. The cells were cultured in Eagle's minimum essential media (EMEM) with supplements and incubated at 5% CO<sub>2</sub> at 37 °C. After a substantial growth period, the U87MG cells were seeded at a density of 5000 cells/well in a 96-well plate and incubated for 24 h. Media without cells were used as a blank, and cells and media without the treatment were used as a control. The cells were treated with EGCG diluted in media and incubated to establish a dose- and time-dependent toxicity effect at concentration ranges of 11, 22, 33, 44, 50, and 200  $\mu$ M. Following 24 and 48 h of incubation with treatment, a 10  $\mu$ L Presto

Blue was added to the plates and incubated for 1 h, and then fluorescence response for Presto Blue was detected at  $I_{\text{Ex}}$  535 nm and  $I_{\text{Em}}$  612 nm. The % cell viability was calculated using eq 1 below.

$$\% \text{Cell Viability} = \left[ \frac{(\text{Fluor. Drug Treatment} - \text{Fluor. Blank})}{(\text{Fluor. Control} - \text{Fluor. Blank})} \right] \times 100 \quad (1)$$

Mean cell viability versus drug concentration was plotted using Prism5 software (GraphPad Software, USA).  $\text{IC}_{50}$  values were calculated as the concentration at which 50% inhibition (decrease in cell proliferation) was achieved.

**Scratch Assay.** U87-MG cells were seeded at 200,000/2 mL/well in 6-well plates. The cells and media with no treatment were used as a control. Once the cells reached confluency, a scratch was made using a sterile tip. The detached cells were washed with phosphate-buffered saline (PBS), and the cells were treated with the  $\text{IC}_{50}$  concentration (24 h) of EGCG. Images were taken over predetermined time points (0, 6, 24, 48, and 72 h) at 4 $\times$  magnification.

**Flow Cytometry.** The U87-MG cells were seeded at 120,000/well in a 12-well plate. After a 24 h incubation period, the cells were treated with  $\text{IC}_{50}$  (24 h) of EGCG and incubated for 24 h. Cells and media with no treatment were used as a control. Following treatment, the cells were washed, trypsinized, and centrifuged at 179g for 5 min. The cell pellets were resuspended and fixed by adding ice-cold 70% ethanol (diluted with PBS). The fixed samples were centrifuged at 179g for 5 min, washed with ice-cold PBS, and then centrifuged again at 179g for 5 min. The fixed cells were resuspended with PBS and transferred to nontissue culture plates/V-shaped. Propidium iodide (500  $\mu\text{g/mL}$  stock) was added to each well, followed by adding RNAase (10 mg/mL), and incubated for 2 h, followed by testing the samples using a flow cytometer. Guava software was used for data analysis to determine the DNA content by fluorescence intensity (488 nm).

**Statistical Analysis.** For statistical analysis, SPSS was used with an independent sample *t*-test for cell cycle to identify significant differences between experimental groups: a two-way ANOVA and a Bonferroni posthoc test were used for cell viability. For the latter, significance between the time points, as well as treatment concentrations, was determined.

**X-ray Crystallography.** rmGPb enzyme crystals were grown using the batch method in a 10 mM BES (pH 6.7) buffer, as described.<sup>30</sup> The crystals were soaked in the crystallization medium enriched with (a) 5 mM EGCG, (b) 5 mM EGCG and 50 mM glucose, and (c) 5 mM EGCG and 10 mM caffeine and incubated for 2 days at 16 °C prior to their flash freezing in a nitrogen stream at 100 K nitrogen using 30% (v/v) DMSO used as a cryoprotectant. X-ray diffraction data were collected by using synchrotron radiation on the P13 beamline at PETRA III (EMBL Hamburg Outstation). The crystallographic suite CCP4<sup>31</sup> was used for data analysis. Data integration and reduction were performed by the programs XDS<sup>32</sup> and AIMLESS.<sup>31</sup> The refinement of the structures was based on previously determined structure [Protein Data Bank (PDB) entry 7P7D]. The model building of the electron density map was performed using the program COOT.<sup>33</sup> Ligand molecule coordinates and topologies were created with the program ACEDRG of the CCP4 suite and were fitted to the electron density maps. The crystallographic refinement of the complexes was performed using maximum likelihood methods by REFMAC5.<sup>34</sup> The programs CONTACT, also in the CCP4i software suite, and PLIP<sup>35</sup> were used for the determination and calculation of protein–ligand interactions. The final structures were optimized using the PDB-REDO server.<sup>36</sup> The program PyMOL<sup>37</sup> was used in order to create graphic designs of the structure.

**In Silico Studies. Protein Preparation.** Muscle and liver isoforms of GP were prepared for computations using Schrödinger's Protein Preparation Wizard<sup>38</sup> applied to the newly solved cocrystallized complex with EGCG (rmGPb, PDB entry: 8QMU, 2.0 Å resolution) and the previously reported complexes with quercetin (rmGPb, PDB entry: 4MRA, 2.34 Å resolution) and *N*-acetyl- $\beta$ -D-glucopyranosyl-

amine (hlGP, PDB entry: 1FC0, 2.40 Å resolution). Water molecules within 5 Å of the native ligands were initially retained (deleted in docking calculations, unless specified), bond orders were assigned, and hydrogens were added, with protonation states for basic/acidic residues assigned from calculated PROPKA<sup>39</sup>  $\text{pK}_a$  values at a pH of 7. Subsequent optimization of hydroxyl groups, His residue protonation states, and potential for its side-chain C/N atom flips, as well as possible side-chain O/N atom flips in Asn and Gln residues, was based on optimizing hydrogen-bonding patterns. Finally, an Impref minimization of the prepared complexes was performed using the OPLS3e force field<sup>40</sup> to relax any steric clashes and/or bad contacts. At the end of the minimization, the RMSDs (heavy atoms) were within 0.3 Å of the crystallographic positions.

**Ligand Preparation.** All ligands were prepared for docking using Maestro and MacroModel 13.0.<sup>38</sup> Each ligand was minimized using 200 steps of the truncated Newton conjugate gradient (TNCG) method,<sup>41</sup> with the OPLS3e force field and water solvation effects accounted for using the generalized Born/surface area (GB/SA) model.

**Glide Docking Calculations.** Docking calculations were performed using Glide 8.9.<sup>38</sup> Using the prepared GPb proteins from PDB entries: 8QMU, 4MRA, and 1FC0 (as described above), the shape and properties of the QBS were mapped onto a grid with dimensions of  $\sim 23.5 \times 23.5 \times 23.5$  Å that were centered on the native ligands; in the case of 1FC0 with no ligand bound at QBS, the position of EGCG from the solved rmGPb–EGCG complex (PDB entry: 8QMU) was superimposed into the binding site for this purpose. Standard parameters were used that included default atomic charges and van der Waals scaling (0.8) for nonpolar ligand atoms to include modest induced-fit effects. Calculations were performed in SP mode with postdocking minimization. Up to five output poses per ligand were saved in each docking calculation.

**Induced-Fit Docking Calculations.** Induced-fit docking (IFD) calculations of EGCG to GP from the solved rmGPb–quercetin complex (PDB code: 4MRA) were performed.<sup>38</sup> The IFD calculations consisted of three stages. In stage I, an initial Glide 8.9 SP docking was performed with a maximum of 20 poses saved. The Arg551 residue was selected for mutation to Ala during this initial docking (rebuilt in stage II). In stage II, the binding site residues Arg551 and Glu120 were refined using Prime 6.2.<sup>42</sup> Finally, in stage III, up to 10 structures from stage II within 30 kcal/mol of the lowest energy structure were employed in Glide-SP ligand redocking calculations. The final predicted complexes ranked by IFD scores were then analyzed in terms of structure and protein–ligand binding interactions.

## RESULTS AND DISCUSSION


**Kinetic Analysis and Synergism.** Kinetic experiments with rmGPb and rmGPa showed that EGCG potently inhibited GP  $K_i = 49.8 \pm 1.6$   $\mu\text{M}$  for rmGPb and  $K_i = 46.7 \pm 1.4$   $\mu\text{M}$  for rmGPa, hence having similar affinity for both muscle GP forms (Table 1). In comparison, the  $K_i$  value of

**Table 1. Values of Inhibition Constants ( $K_i$ ) for EGCG, EGC, and Quercetin toward GP Isoforms**

GP isoform	EGCG, $K_i$ ( $\mu\text{M}$ )	EGC, $K_i$ ( $\mu\text{M}$ )	Quercetin, $K_i$ ( $\mu\text{M}$ ) <sup>44</sup>
rmGPa	$46.7 \pm 1.4$		$32.93 \pm 2.49$
rmGPb	$49.8 \pm 1.6$	$285.5 \pm 14.1$	$69.12 \pm 4.71$
hlGPa	$17.6 \pm 0.7$		$43.52 \pm 1.65$


EGC was calculated to be  $285.5 \pm 14.1$   $\mu\text{M}$  for rmGPb and the  $\text{IC}_{50}$  value for hlGPa was  $193.8 \pm 3.5$   $\mu\text{M}$ , revealing that the gallate group of EGCG confers potency. Furthermore, the inspection of the Lineweaver–Burk plots (Figure 2) revealed that EGCG and EGC are noncompetitive inhibitors.





**Figure 2.** Inhibition of (A) rmGPα, (B) rmGPβ, and (C) hGPα by EGCG and (D) by EGC. Lineweaver–Burk plots of reciprocal velocities versus reciprocal G1P concentrations at different EGCG concentrations and constant concentrations of glycogen (0.2% w/v) and AMP (1 mM) for rmGPβ. (A, B) EGCG concentrations were 0 μM, 20 μM, 40 μM, 60 μM, 80 μM and 100 μM. (C) EGCG concentrations were 0, 20, 50 and 80 μM. (D) EGC concentrations were 0, 40, 80, 180, 250, and 350 μM. The diagrams of each velocity ( $V$ ) in  $y/y$  at different substrate concentrations in  $x/x$  are shown in the insets.

The inhibitory properties for more potent EGCG were further investigated with respect to well-known inhibitors glucose, caffeine, and AMP that bind at the catalytic, inhibitor, and allosteric GP sites, respectively. The Dixon plots of  $1/v$  versus  $[EGCG]$  at varying concentrations of caffeine (Figure 3a) showed that the curves intersect above the horizontal axis, revealing cooperative inhibitor binding. The Dixon plots (Figure 3b) in the case of glucose are indicative of synergistic inhibition of a competitive inhibitor (glucose) with a




**Figure 3.** Multiple inhibition studies. Dixon plots of reciprocal velocity versus EGCG concentrations at different concentrations of (A) caffeine, (B) glucose, and (C) AMP. In panels (A, B), the samples were assayed at constant concentrations of Glc-1-P (10 mM), AMP (1 mM), and glycogen (0.2% w/v). (C) Concentrations of AMP varied from 0 to 0.5 mM.

noncompetitive one (EGCG). The Dixon plots of  $1/v$  versus  $[EGCG]$  at varying AMP concentrations (Figure 3c) showed curve intersections below the horizontal axis, indicating that binding of an inhibitor hinders the binding of the other.<sup>43</sup>

Kinetic studies with the physiological target hGPα isoform also revealed that EGCG is a noncompetitive inhibitor with  $K_i = 17.6 \pm 0.7$  μM (Table 1 and Figure 2c) about 3 times lower  $K_i$  value compared with the muscle isoforms. This difference in  $K_i$  values among the liver and muscle GP isoforms is more pronounced in comparison to quercetin,<sup>44</sup> which is almost equipotent for rmGP and hGPα. This new result is encouraging, as it indicates an element of tissue selectivity

for EGCG-like inhibitors. The efficacy of EGCG to inhibit GP was further assessed (Figure 4) in ex vivo system of




**Figure 4.** (A) Viability of HepG2 cells upon 3 h treatment with EGCG measured by applying the MTT assay. The vehicle-treated control cells were set at 100%. No statistical differences were observed. (B) Diagram of hGPα activity in the presence of increasing concentrations of EGCG, caffeine, and simultaneous incubation of HepG2 cells with EGCG and caffeine. GPα activity is expressed as nmol/min/mg protein and calculated using 5 time points and errors (shown on bars). The same experimental conditions were conducted twice for each sample. Data were analyzed by one- and two-way ANOVA, followed by Tukey's posthoc test, using StatPlusLE 7.3.0 software, and expressed as mean  $\pm$  SD ( $n = 2$ ). \* $p \leq 0.05$ , \*\* $p \leq 0.01$ ; \*\*\* $p \leq 0.001$ .

hepatocarcinoma HepG2 cells in culture. Prior to experiments, the toxicity of EGCG toward HepG2 cells was assessed, and no toxicity was observed upon 3 h up to 100  $\mu$ M. The activity of GP was assessed after treatment with 60 and 100  $\mu$ M EGCG, as described in the Materials and Methods section, and the results showed 31.8 and 43.5% reduction in GP activity, respectively. Furthermore, the effect of EGCG on GP

inhibition in HepG2 cells in the presence of caffeine was also assessed. It is demonstrated in Figure 4B that the treatment of cells with 200  $\mu$ M caffeine caused 22.3% inhibition in GP activity, and the percentage of inhibition was increased to 52.9% after cotreatment with 100  $\mu$ M EGCG. The results are in agreement with in vitro assays, showing that caffeine and EGCG are nonexclusive inhibitors that bind at different sites of GP, and their synergistic effect is also exhibited in HepG2 cells. To our knowledge, it is the first time that synergy in cells was shown for inhibitors other than glucose.

**Effect of EGCG on Glioblastoma.** The anticancer potential of EGCG against U87-MG cells was determined following 24 and 48 h of treatment. Each time point presented a significant reduction in overall cell viability following treatment with EGCG, with a significant reduction in the cell viability of the treated cells from log [EGCG] =  $-4.7$  (i.e., 22  $\mu$ M) onward (Figure 5A).

U87-MG cells demonstrated a significant decrease in cell viability when incubated with EGCG with  $IC_{50}$  values of  $30.5 \pm 0.4$  and  $24 \pm 2.7$   $\mu$ M at 24 and 48 h, respectively. These results were in line with studies that reported a decrease in cell viability at 50  $\mu$ M after a 24 h period<sup>45</sup> and at 25  $\mu$ M after 48 h of treatment.<sup>46</sup> It is worth mentioning that there was no significant difference ( $p > 0.05$ ) between 24 and 48 h  $IC_{50}$  values, indicating that the inhibition in the cell viability was achieved in the first 24 h, following treatment with EGCG, and slightly increased following 48 h. From the wound/scratch assay experiments (Figure 5B,C), the inhibition of cell migration via EGCG of U87-MG cells was tested over various time points. Following the treatment with  $IC_{50}$  concentration of EGCG (30.5  $\mu$ M) at an early time point (6 h), the U87-MG cells showed a significant reduction in cell migration, where the % wound closure was 16% ( $p < 0.005$ ), as demonstrated in Figure 5C, in comparison to the control-non-treated U87-MG cell lines, where the % wound closure was around 50%. In addition, at 24 h of treatment, a 68% wound closure ( $p < 0.05$ ) was observed; a similar 67.5% wound closure at 24 h has been reported for another natural product GP inhibitor luteolin ( $IC_{50}(GP\alpha) = 15.6$   $\mu$ M;  $IC_{50}(GP\beta) = 28.8$   $\mu$ M)<sup>23</sup> in the same cell line at 30  $\mu$ M concentration.<sup>47</sup> Interestingly, the control cells exhibited 100% wound closure (no visible wound) in both 48 and 72 h (Figure 5B,C), while U87-MG cells treated with EGCG still exhibited a significant reduction of % wound closure with 70 and 73% ( $p < 0.001$  and  $p < 0.005$ ) for 48 and 72 h, respectively. This suggests the potential of EGCG to limit cell proliferation and migration in GBM. During the cell cycle study (Figure 5D), the control U87-MG had the highest percentage of cells in the G0/G1 phase at  $53.067 \pm 3.623\%$ , followed by  $18.747 \pm 1.786$  and  $14.960 \pm 0.442\%$  for G2/M and S phases, respectively. In comparison, U87-MG cells treated with  $IC_{50}$  of EGCG showed significant differences, with a cell prevalence of  $45.770 \pm 1.683\%$  for G0/G1 (predominant phase), followed by  $29.810 \pm 3.352\%$  at the G2/M phase and  $14.885 \pm 3.472\%$  for the S phase. EGCG-treated cells were therefore associated with a decrease of cells in the G0/G1 phase and concomitant increases in the G2/M phase. In line with the potential role of GP, EGCG is known to increase the accumulation of p53 in cancerous cell lines.<sup>48</sup> In GBM in vitro and in vivo studies, liver isoform depletion led to increased levels of p53; in vivo, consequent glycogen accumulation led to increased reactive oxygen species that contributed to a p53-dependent induction of senescence and impaired tumori-




**Figure 5.** Effect of EGCG on GBM. (A) % Cell viability and effect of EGCG over 24 and 48 h against U87-MG cells ( $N = 3$ , mean/SD). The cells were treated with 11, 22, 33, 44, 50, and 200  $\mu\text{M}$  concentrations.  $\text{IC}_{50}$  values of  $30.5 \mu\text{M} \pm 0.4$  and  $24 \mu\text{M} \pm 2.7$  at 24 and 48 h were observed, respectively. (B) Wound/scratch assay ( $N = 3$ ) for U87-MG cells treated with the  $\text{IC}_{50}$  concentration ( $30.5 \mu\text{M}$ ) of EGCG compared against a control over 72 hours. The images are captured at 4X magnification (scale 0–10 mm in 0.1 mm). (C) Bar chart representing the % wound closure following treatment with EGCG  $\text{IC}_{50}$  concentration ( $30.5 \mu\text{M}$ ) over a period of 72 h in comparison with control nontreated U87-MG cell lines. (D) Cell cycle analysis of U87-MG cells ( $N = 3$ , mean/SD), represented as the percentage prevalence of G0/G1, S and G2/M cell cycle phases. EGCG-treated U87-MG cells were compared for significance against untreated control cells.  $P$ -values  $\leq 0.05$  were considered statistically significant with significance indicated in figures as ns,  $p > 0.05$ , \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$ , and \*\*\*  $p \leq 0.001$ .

genesis.<sup>6</sup> Nevertheless, the anticancer therapeutic potential of GP inhibition should be further explored in the future through the discovery of less promiscuous than EGCG and more specific GP inhibitors.

**Binding at the Quercetin Binding Site of rmGPb.** In order to elucidate the structural basis of inhibition of GP by EGCG, we determined, using X-ray crystallography, the structure of the rmGPb-EGCG complex (PDB entry: 8QMU) at a 2.0 Å resolution and the complexes rmGPb-EGCG-glucose (PDB entry: 8R53) and rmGPb-EGCG-caffeine (PDB entry: 8R6V) at 2.0 and 2.5 Å, respectively. The data processing and refinement statistics are shown in Table S1. A–C. Inspection of the 2Fo–Fc electron density maps in all complexes revealed a positive peak at the site of

rmGPb, as previously recognized<sup>13</sup> to bind quercetin. The QBS is located close to the protein surface about 15 Å from the active site, 43 Å from the allosteric site, and 32 Å from the inhibitor site. It forms a groove constellated by residues Lys544, Arg551, Lys655, and Tyr548 on one side and by Glu120 and Glu123 on the other side. Upon binding, EGCG makes a total of 107 van der Waals (vdw) interactions (14 polar–polar, 39 nonpolar–nonpolar, and 54 polar–non polar interactions). A detailed description of protein–ligand interactions is given in Table S2 in the Supporting Information. The ring B hydroxyl oxygen atoms (O1), (O7), and (O37) and the hydroxyl oxygen (O44) of the gallate group form 5 hydrogen bonds (hb) with protein atoms (Table S2.A–Supporting Information).




**Figure 6.** Binding of EGCG at the QBS of rmGPb. (A) Fo-Fc electron density map, contoured at  $3\sigma$ , for the bound state of EGCG (green) at rmGPb. (B) Stereo diagram of binding of EGCG to the QBS of rmGPb. Hydrogen-bonding interactions are represented by dotted lines and water molecules as spheres. (C) Superposition of EGCG-rmGPb (cyan) and EGC-rmGPb (magenta) complexes, where a shift of Glu120 was observed due to the gallate ring of EGCG.

In addition, 2 water-mediated bridges with protein residues are formed, namely, O02-Wat1037-Cys495 (O) and O03-Wat1134-Asn541 (OD1). O02 also forms an hb with Wat35. Overall, 8 hb are formed. Aromatic rings A and B are positioned in 4.06 and 3.20 Å of positively charged Lys544 and Arg551, respectively, forming cation- $\pi$  interactions. (Figure 6B).

Superposition of the native rmGPb T state (PDB entry 7P7D) structure onto the rmGPb-EGCG complex structure, residues (7-836), showed RMSD values of 0.244 Å on C $\alpha$  atoms and 0.260 and 0.613 Å for main-chain and side-chain atoms, respectively. Structural determination of the complexes of rmGPb-EGCG-glucose and rmGPb-EGCG-caffeine demonstrated that EGCG can bind at the QBS simultaneously with glucose at the catalytic site or caffeine at the inhibitor site, in





**Figure 7.** Binding of EGC at the QBS of rmGPb. (A) Fo-Fc electron density map, contoured at  $3\sigma$ , for the bound of EGC (yellow) at rmGPb. (B) Stereo diagram of the binding of EGC to the QBS of rmGPb. Hydrogen-bonding interactions are represented by dotted lines and water molecules as spheres.

good agreement with the synergistic behavior from the multiple inhibition studies described above. The ligand–protein interactions for all solved complexes are summarized in [Tables S2 and S4](#) Supporting Information. Superposition of the complex of rmGPb-EGCG with the rmGPb-EGCG-glucose complex showed no significant overall conformational changes with RMSD values of 0.205 Å on Cα atoms and 0.235 and 0.598 Å for main-chain and side-chain atoms, respectively. Superposition of rmGPb-EGCG-glucose with rmGPb-glucose (PDB entry 2PYD) showed no differences in protein–glucose interactions, while the RMSD values for Cα atoms were 0.174, 0.225, and 0.963 Å for main-chain and side-chain atoms, respectively. Likewise, the superposition of the binary complex of rmGPb-EGCG with the rmGPb-EGCG-cafeine complex showed no significant overall conformational changes with RMSD values of 0.234 Å on Cα atoms and 0.268 and 0.692 Å for main-chain and side-chain atoms, respectively. No significant differences in the number of vdw interactions and no changes in hb interactions with protein atoms were observed although the water-mediated hb interactions were less due to a lower resolution for the rmGPb-EGCG-cafeine complex. In addition, the superposition of rmGPb-EGCG-cafeine with rmGPb-cafeine (PDB, 1GFZ) showed RMSD values of 0.406 Å on Cα atoms and 0.427 and 1.217 Å for main-chain and side-chain atoms, respectively. Interestingly, in the case of the rmGPb-EGCG-cafeine complex, caffeine forms an extra water-mediated hb and more (23) vdw interactions at the inhibitor site when EGCG is bound. This difference can be attributed to the effect of the EGCG binding on increasing the caffeine interactions with the protein in favor of T-state stabilization although differences in experimental conditions for both complexes should also be considered.

The structure of the rmGPb-EGC complex (PDB entry: 8RS2) was also determined with a 2.1 Å resolution ([Table S1.D](#), Supporting Information). The 2Fo–Fc map also showed that EGC binds at the QBS although a high concentration of EGC (15 mM, 3× more than EGCG) was needed in order to achieve binding, reflecting its low potency toward GP. Superposition of the rmGPb-EGC complex structure with the rmGPb T state (PDB entry 7P7D) and residues (7–836) showed RMSD values of 0.229 Å on Cα atoms and 0.249 and 0.665 Å for main-chain and side-chain atoms, respectively. EGC forms 22 less van der Waals interactions (overall 85, 7 polar–polar, 37 nonpolar–nonpolar, and 41 polar–nonpolar) compared to EGCG. The lack of the gallate group and its hydroxyls explains differences mostly in polar interactions and also in hb bonding ([Table S2.B](#), Supporting Information).

EGC forms 3 hb with protein residues in comparison to 5 of EGCG. The hydroxyl oxygen (O17) forms a hb with Wat1876. The hydroxyl oxygen O19 of ring A makes 2 water-bridged interactions: the water-bridged interactions O19–Wat1037–Cys495 (O) and the water-bridged interactions O19–Wat1847–Leu494 (O) and the hydrogen-bridged interactions 1 hb with Wat1848. In addition, (O21) forms 1 hb with Wat1103, and the overall EGC forms 8 hb interactions. Arg551 is at a 3.58 Å distance from ring B and Lys544 is at a distance of 3.23 Å from ring A, participating in  $\pi$ –cation interactions ([Figure 7](#)).


**Contribution of the Gallate Group in EGCG to Binding.** The gallate group (ring D) of EGCG forms 2 extra hydrogen bonds through its hydroxyl oxygens (O37) and (O44) compared with the nongallated EGC, with residues Tyr548 (N) and Glu120 (OE2), respectively. Superposition of the binary complexes of rmGPb-EGCG with rmGPb-EGC reveals a shift (RMSD, 3.31 Å) of the Glu120(OE2) side chain upon EGCG binding due to its hydrogen-bonding interaction with hydroxyl oxygen (O44) of the gallate group ([Figure 6C](#)). The same shift (RMSD, 2.77 Å) of Glu120 is also observed in comparison with the rmGPb-quercetin complex. Glu120 is located near the entrance of QBS, and its participation in hb confers plasticity to the site that could be exploited upon ligand binding.

**Comparison with Quercetin Binding.** Superpositions of rmGPb-EGCG and rmGPb-EGC with the rmGPb-quercetin complex (PDB entry 4MRA) showed that EGCG and EGC adopt the same binding orientation with no overall significant conformational changes. In comparison to quercetin, EGCG having an extra ring (ring D) forms overall more vdw interactions (107 compared to 63 for quercetin). Upon binding, quercetin exploits 6 hydrogen bonds (3 with water molecules) and  $\pi$ –cation interactions with Lys544, Lys655, and Arg551 although it does not form a hb with Arg551. EGCG forms 2 extra hb with protein residues exhibiting greater potency (×1.4 times).

**Differences in EGCG Binding for Muscle and Liver GP Isoforms.** Sequence alignment using T-Coffee<sup>49</sup> of the rabbit/human muscle GP and human GP liver isoforms ([Figure S1](#), Supporting Information) revealed that although most of the residues decorating the QBS are conserved, Tyr548 in muscle is a Phe in liver, but, most importantly, the key interacting Arg551 residue at the entrance of the site in muscle GP is in fact a Lys in the brain and a Thr in liver GP isoform. This shorter polar Thr “opens” the entrance of the QBS, allowing for different interactions with ligands. Actually, the distance between the gating residues Arg551 (CZ) and Glu120 (OE2)

is 6.97 Å in muscle isoform and is 4.63 Å shorter compared to a distance of 11.71 Å between Thr551 (OG1) and Glu120 (OE1) in liver isoform. This observation leads to the assumption of a different binding mode of EGCG for muscle and liver isoforms, justifying differences in  $K_i$  values (Table 1), as shown by kinetic analysis. To probe the potential for EGCG binding differences to the muscle and liver GP isoforms, docking calculations of EGCG to the solved human liver GP isoform of PDB entry: 1FC0 were performed. As an initial test of the application of the Glide-SP docking method for this application, EGCG was redocked to the solved muscle EGCG-rmGPb complex reported here (PDB entry: 8QMU) and reproduced well the crystallographic conformation, with a ligand RMSD (heavy atoms) of 0.683 Å for the top-ranked binding pose. As a more challenging test, EGCG was cross-docked to the solved muscle GPb structure from its solved complex with quercetin (PDB entry: 4MRA). In this case, none of the predicted poses reproduced the EGCG crystallographic conformation. It was speculated that the positioning of Arg551 was a key factor in this regard so that IFD calculations were performed toward confirming this hypothesis. In the IFD, Arg551 was mutated to an Ala residue in the initial Glide-SP docking stage before the residue was rebuilt, and the complex was refined using Prime before a final Glide-SP docking stage (c.f. computational details). The Glu120 residue due to its shifted position (Figure 6C) was also included in the refinement. Applying this protocol, ten predicted protein–ligand complexes were returned, one of which was the crystallographic pose (PDB entry: 8QMU) with a ligand RMSD (heavy atoms) of 0.961 Å (after protein backbone superimposition). Crucially, Arg551 side-chain orientations were diverse in the returned predicted complexes, and only when Arg551 was close to its correct crystallographic position was the correct pose of EGCG predicted, highlighting the key role of Arg551 on ligand binding modes. Arg551 is Thr551 in the liver GP isoform, and hence, based on the above analysis, we expected that a different ligand binding pose of EGCG would be predicted for docking to human liver GP. This indeed was the case. Five ligand poses were saved, all of which were close to the same location and binding shape in the QBS but different from those observed for muscle GP. Inspection of the binding poses revealed that EGCG adopted a different binding orientation and exploited a different network of protein–ligand interactions compared to rmGP (Figure 8). The top-ranked binding pose of EGCG exploits 7 hb interactions with protein atoms (Table S3, Supporting Information).

This binding orientation allows 2 more direct hydrogen bonds with protein atoms compared to those in the rmGPb complex (the rest are water-mediated). Lys655 (NZ) is positioned at 4.33 Å from the center of ring D forming a cation– $\pi$  interaction, further stabilizing the complex (Figure 8A). The nearby Phe548 can also be exploited for  $\pi$ –stacking interactions (T-shaped), as revealed by docking poses 2–5 (Figure 8B). Hence, the differences in  $K_i$  values for muscle versus liver GP isoforms (selectivity of EGCG for liver isoform) seem to be well explained by structural analysis, and in particular, the influence of Thr551 versus Arg551 in ligand binding at the QBS (Figure 8C). Hence, the development of EGCG-like inhibitors that target QBS could be considered a good starting point for the design of liver-selective GP inhibitors with the potential against different diseases. Overall, EGCG binding at the QBS offers new opportunities for the



**Figure 8.** Different binding modes of EGCG for muscle and liver GP isoforms. (A) Stereo diagram of the top-ranked predicted binding pose of EGCG (green) binding to the QBS of hGPa from Glide-SP docking. Hydrogen-bonding interactions are represented by dotted lines. (B) Superposition of the other four predicted poses for binding of EGCG to hGPa. (C) Different binding modes of EGCG binding between rmGPb (cyan) and hGPa (light pink) is demonstrated. The difference in the distance between Arg551 and Glu120 in the muscle isoform and between Thr551 and Glu120 in the liver isoform is represented by dotted lines.

design of liver-selective GP inhibitors while also revealing a potential role of ligand-induced inhibition of GP against cancers such as GBM.

## ■ ASSOCIATED CONTENT

### SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jafc.4c06920>.

Sequence alignment figure of GP isoforms (Figure S1); summary of the diffraction, data processing, and refinement statistics for the rmGPb complexes (Table S1. A–D); all hydrogen bonds that EGCG form with rmGPb residues (Table S2); all hydrogen bonds that EGCG form with hGPb residues (Table S3); and all the interactions that EGCG, EGC, glucose, and caffeine form with glycogen phosphorylase residues in the crystal (Table S4. A–I.); locations of different binding sites in GP monomer (Figure S2); further figures comparing EGCG and quercetin binding at QBS (Figures S3–S4) (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

Vasiliki Skamnaki – Department of Biochemistry and Biotechnology, University of Thessaly, Larisa 41500, Greece; [orcid.org/0000-0002-0870-3128](https://orcid.org/0000-0002-0870-3128); Email: [vskamnaki@bio.uth.gr](mailto:vskamnaki@bio.uth.gr)

### Authors

Serafeim Alexopoulos – Department of Biochemistry and Biotechnology, University of Thessaly, Larisa 41500, Greece

Megan McGawley – School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, U.K.

Roshini Mathews – School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, U.K.

Souzana Papakostopoulou – Department of Biochemistry and Biotechnology, University of Thessaly, Larisa 41500, Greece

Symeon Koulas – Department of Biochemistry and Biotechnology, University of Thessaly, Larisa 41500, Greece

Demetres D. Leonidas – Department of Biochemistry and Biotechnology, University of Thessaly, Larisa 41500, Greece

Tamara Zwain – School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, U.K.

Joseph M. Hayes – School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, U.K.; [orcid.org/0000-0002-7745-9616](https://orcid.org/0000-0002-7745-9616)

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.jafc.4c06920>

### Funding

The open access publishing of this article is financially supported by HEAL-Link.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We acknowledge support of this work by the project “The National Research Infrastructures on integrated biology, drug screening efforts and drug target functional characterization—INSPIRED-Thessaly” (MIS 5002550), which is implemented

under the Action “Reinforcement of the Research and Innovation Infrastructure”, funded by the Operational Program “Competitiveness, Entrepreneurship, and Innovation” (NSRF 2014–2020) and cofinanced by Greece and the European Union (European Regional Development Fund). Also, we would like to acknowledge funding from the Research Centre for Brain and Behaviour, UCLan.

## ■ ABBREVIATIONS USED

DMEM, Dulbecco's modified Eagle's medium; EGC, epigallocatechin; EGCG, epigallocatechin gallate; EMEM, Eagle's minimum essential media; FBS, fetal bovine serum; G1P, glucose-1-phosphate; GB/SA, generalized born/surface area model; GBM, glioblastoma; GP, glycogen phosphorylase; hGP, human liver GP; hGPb, human liver glycogen phosphorylase GPb; MTT, 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; PhKytnc, constitutively active kinase domain of glycogen phosphorylase kinase; PDB, Protein Data Bank; QBS, quercetin binding site; rmGPb, rabbit skeletal muscle glycogen phosphorylase b; TNCG, truncated Newton conjugate gradient method; T2D, type 2 diabetes; IFD, induced-fit docking

## ■ REFERENCES

- (1) Rines, A. K.; Sharabi, K.; Tavares, C. D.; Puigserver, P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. *Nature reviews. Drug discovery* **2016**, *15*, 786–804.
- (2) Zois, C. E.; Harris, A. L. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. *J. Mol. Med. (Berl)* **2016**, *94*, 137–154.
- (3) Curtis, M.; Kenny, H. A.; Ashcroft, B.; Mukherjee, A.; Johnson, A.; Zhang, Y.; Helou, Y.; Battle, R.; Liu, X.; Gutierrez, N.; Gao, X.; Yamada, S. D.; Lastra, R.; Montag, A.; Ahsan, N.; Locasale, J. W.; Salomon, A. R.; Nebreda, A. R.; Lengyel, E. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. *Cell Metab.* **2019**, *29*, 141–155.e9.
- (4) Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. *Expert Opin Investig Drugs* **2001**, *10*, 439–54.
- (5) Agius, L. Role of glycogen phosphorylase in liver glycogen metabolism. *Mol. Aspects Med.* **2015**, *46*, 34–45.
- (6) Favaro, E.; Bensaad, K.; Chong, M. G.; Tennant, D. A.; Ferguson, D. J.; Snell, C.; Steers, G.; Turley, H.; Li, J. L.; Gunther, U. L.; Buffa, F. M.; McIntyre, A.; Harris, A. L. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. *Cell Metab* **2012**, *16*, 751–64.
- (7) Zois, C. E.; Hendriks, A. M.; Haider, S.; Pires, E.; Bridges, E.; Kalamida, D.; Voukantis, D.; Lagerholm, B. C.; Fehrmann, R. S. N.; den Dunnen, W. F. A.; Tarasov, A. I.; Baba, O.; Morris, J.; Buffa, F. M.; McCullagh, J. S. O.; Jalving, M.; Harris, A. L. Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation. *Cell Death Dis.* **2022**, *13*, 573.
- (8) Zhao, C. Y.; Hua, C. H.; Li, C. H.; Zheng, R. Z.; Li, X. Y. High PYGL Expression Predicts Poor Prognosis in Human Gliomas. *Front Neurol* **2021**, *12*, No. 652931.
- (9) Mathomes, R. T.; Koulas, S. M.; Tsialtas, I.; Stravodimos, G.; Welsby, P. J.; Psarra, A. G.; Stasik, I.; Leonidas, D. D.; Hayes, J. M. Multidisciplinary docking, kinetics and X-ray crystallography studies of baicalein acting as a glycogen phosphorylase inhibitor and determination of its' potential against glioblastoma in cellular models. *Chem. Biol. Interact* **2023**, *382*, No. 110568.
- (10) Leonidas, D. D.; Zographos, S. E.; Tsitsanou, K. E.; Skamnaki, V. T.; Stravodimos, G.; Kyriakis, E. Glycogen phosphorylase revisited: extending the resolution of the R- and T-state structures of the free



enzyme and in complex with allosteric activators. *Acta Crystallogr. F Struct Biol. Commun.* **2021**, *77*, 303–311.

(11) Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; Gavalas, N. G.; Johnson, L. N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. *Structure* **2000**, *8*, 575–584.

(12) Chrysina, E. D.; Kosmopoulou, M. N.; Tiraidis, C.; Kardakaris, R.; Bischler, N.; Leonidas, D. D.; Hadady, Z.; Somsak, L.; Docsa, T.; Gergely, P.; Oikonomakos, N. G. Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1, 3, 4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. *Protein Sci.* **2005**, *14*, 873–88.

(13) Kantsadi, A. L.; Apostolou, A.; Theofanous, S.; Stravodimos, G. A.; Kyriakis, E.; Gorgogietas, V. A.; Chatzileontiadou, D. S.; Pegiou, K.; Skamnaki, V. T.; Stagos, D.; Kouretas, D.; Psarra, A. M.; Haroutounian, S. A.; Leonidas, D. D. Biochemical and biological assessment of the inhibitory potency of extracts from vinification byproducts of *Vitis vinifera* extracts against glycogen phosphorylase. *Food Chem. Toxicol.* **2014**, *67*, 35–43.

(14) Kyriakis, E.; Solovou, T. G. A.; Kun, S.; Czifrak, K.; Szocs, B.; Juhasz, L.; Bokor, E.; Stravodimos, G. A.; Kantsadi, A. L.; Chatzileontiadou, D. S. M.; Skamnaki, V. T.; Somsak, L.; Leonidas, D. D. Probing the beta-pocket of the active site of human liver glycogen phosphorylase with 3-(C-beta-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors. *Bioorg Chem.* **2018**, *77*, 485–493.

(15) Kyriakis, E.; Stravodimos, G. A.; Kantsadi, A. L.; Chatzileontiadou, D. S.; Skamnaki, V. T.; Leonidas, D. D. Natural flavonoids as antidiabetic agents. The binding of gallic and ellagic acids to glycogen phosphorylase b. *FEBS letters* **2015**, *589*, 1787–94.

(16) Bokor, E.; Kyriakis, E.; Solovou, T. G. A.; Koppany, C.; Kantsadi, A. L.; Szabo, K. E.; Szakacs, A.; Stravodimos, G. A.; Docsa, T.; Skamnaki, V. T.; Zographos, S. E.; Gergely, P.; Leonidas, D. D.; Somsak, L. Nanomolar Inhibitors of Glycogen Phosphorylase Based on beta-d-Glucosaminyl Heterocycles: A Combined Synthetic, Enzyme Kinetic, and Protein Crystallography Study. *J. Med. Chem.* **2017**, *60*, 9251–9262.

(17) Bokor, E.; Kun, S.; Goyard, D.; Toth, M.; Praly, J. P.; Vidal, S.; Somsak, L. C-Glucopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential. *Chem. Rev.* **2017**, *117*, 1687–1764.

(18) Kun, S.; Begum, J.; Kyriakis, E.; Stamati, E. C. V.; Barkas, T. A.; Szennyes, E.; Bokor, E.; Szabo, K. E.; Stravodimos, G. A.; Sipos, A.; Docsa, T.; Gergely, P.; Moffatt, C.; Patraskaki, M. S.; Kokolaki, M. C.; Gkerdi, A.; Skamnaki, V. T.; Leonidas, D. D.; Somsak, L.; Hayes, J. M. A multidisciplinary study of 3-(beta-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors. *Eur. J. Med. Chem.* **2018**, *147*, 266–278.

(19) Hayes, J. M.; Kantsadi, A. L.; Leonidas, D. D. Natural products and their derivatives as inhibitors of glycogen phosphorylase: potential treatment for type 2 diabetes. *Phytochem. Rev.* **2014**, *13*, 471–498.

(20) Leonidas, D. D.; Hayes, J. M.; Kato, A.; Skamnaki, V. T.; Chatzileontiadou, D. S.; Kantsadi, A. L.; Kyriakis, E.; Chetter, B. A.; Stravodimos, G. A. Phytogetic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes. *Curr. Med. Chem.* **2017**, *24*, 384–403.

(21) Tauber, A. L.; Schweiker, S. S.; Levonis, S. M. From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer. *Nutr. Res. (N.Y.)* **2020**, *74*, 23–36.

(22) Casanova, E.; Salvado, J.; Crescenti, A.; Gibert-Ramos, A. Epigallocatechin Gallate Modulates Muscle Homeostasis in Type 2 Diabetes and Obesity by Targeting Energetic and Redox Pathways: A Narrative Review. *Int. J. Mol. Sci.* **2019**, *20*, 532.

(23) Jakobs, S.; Fridrich, D.; Hofem, S.; Pahlke, G.; Eisenbrand, G. Natural flavonoids are potent inhibitors of glycogen phosphorylase. *Mol. Nutr. Food Res.* **2006**, *50*, 52–7.

(24) Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki, V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. *J. Biol. Chem.* **2000**, *275*, 34566–73.

(25) Drakou, C. E.; Gardeli, C.; Tsialtas, I.; Alexopoulos, S.; Mallouchos, A.; Koulas, S. M.; Tsagkarakou, A. S.; Asimakopoulos, D.; Leonidas, D. D.; Psarra, A. G.; Skamnaki, V. T. Affinity Crystallography Reveals Binding of Pomegranate Juice Anthocyanins at the Inhibitor Site of Glycogen Phosphorylase: The Contribution of a Sugar Moiety to Potency and Its Implications to the Binding Mode. *J. Agric. Food Chem.* **2020**, *68*, 10191–10199.

(26) Hayes, J. M.; Skamnaki, V. T.; Archontis, G.; Lamprakis, C.; Sarrou, J.; Bischler, N.; Skaltsounis, A. L.; Zographos, S. E.; Oikonomakos, N. G. Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined. *Proteins* **2011**, *79*, 703–19.

(27) Oikonomakos, N. G. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. *Current protein & peptide science* **2002**, *3*, 561–86.

(28) Leatherbarrow, R. J. *GraFit Version 6.0*; Erithakus Software: Staines, UK, 2007.

(29) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol Methods* **1983**, *65*, 55–63.

(30) Fischer, T.; Koulas, S. M.; Tsagkarakou, A. S.; Kyriakis, E.; Stravodimos, G. A.; Skamnaki, V. T.; Liggri, P. G. V.; Zographos, S. E.; Riedl, R.; Leonidas, D. D. High Consistency of Structure-Based Design and X-Ray Crystallography: Design, Synthesis, Kinetic Evaluation and Crystallographic Binding Mode Determination of Biphenyl-N-acyl-beta-d-Glucopyranosylamines as Glycogen Phosphorylase Inhibitors. *Molecules* **2019**, *24*, 1322.

(31) Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr. D Biol. Crystallogr.* **1994**, *50*, 760–763.

(32) Kabsch, W. Xds. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66*, 125–32.

(33) Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallographica Section D-Biological Crystallography* **2004**, *60*, 2126–2132.

(34) Murshudov, G. N.; Skubak, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures. *Acta crystallographica. Section D, Biological crystallography* **2011**, *67*, 355–67.

(35) Adasme, M. F.; Linnemann, K. L.; Bolz, S. N.; Kaiser, F.; Salentin, S.; Haupt, V. J.; Schroeder, M. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. *Nucleic Acids Res.* **2021**, *49*, W530–W534.

(36) Joosten, R. P.; Long, F.; Murshudov, G. N.; Perrakis, A. The PDB\_REDO server for macromolecular structure model optimization. *IUCrJ.* **2014**, *1*, 213–20.

(37) DeLano, W. L. *The PyMOL Molecular Graphics System*; DeLano Scientific: Palo Alto, CA, USA, 2002.

(38) *Schrödinger Software Suite 2020–4*; L. N. Y.: NY, 2020.

(39) Sondergaard, C. R.; Olsson, M. H.; Rostkowski, M.; Jensen, J. H. Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. *J. Chem. Theory Comput* **2011**, *7*, 2284–95.

(40) Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J. Chem. Theory Comput* **2016**, *12*, 281–96.



- (41) Ponder, J. W.; Richards, F. M. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. *J. Mol. Biol.* **1987**, *193*, 775–91.
- (42) Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J.; Honig, B.; Shaw, D. E.; Friesner, R. A. A hierarchical approach to all-atom protein loop prediction. *Proteins* **2004**, *55*, 351–67.
- (43) Segel, I. H. *Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems*; Wiley, 1993, 992.
- (44) Chetter, B. A.; Kyriakis, E.; Barr, D.; Karra, A. G.; Katsidou, E.; Koulas, S. M.; Skamnaki, V. T.; Snape, T. J.; Psarra, A. G.; Leonidas, D. D.; Hayes, J. M. Synthetic flavonoid derivatives targeting the glycogen phosphorylase inhibitor site: QM/MM-PBSA motivated synthesis of substituted 5,7-dihydroxyflavones, crystallography, in vitro kinetics and ex-vivo cellular experiments reveal novel potent inhibitors. *Bioorg Chem.* **2020**, *102*, No. 104003.
- (45) Das, A.; Banik, N. L.; Ray, S. K. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. *Cancer* **2009**, *116*, 164–176.
- (46) Yokoyama, S. H.; Wakimaru, H.; Sarker, N.; K, P.; Kuratsu, J. Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro. *Neuro Oncol.* **2001**, *3*, 22–28.
- (47) Cheng, W. Y.; Chiao, M. T.; Liang, Y. J.; Yang, Y. C.; Shen, C. C.; Yang, C. Y. Luteolin inhibits migration of human glioblastoma U-87 MG and T98G cells through downregulation of Cdc42 expression and PI3K/AKT activity. *Mol. Biol. Rep* **2013**, *40*, 5315–26.
- (48) Gu, J. J.; Qiao, K. S.; Sun, P.; Chen, P.; Li, Q. Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway. *Eur. Rev. Med. Pharmacol. Sci.* **2018**, *22*, 4557–4563.
- (49) Notredame, C.; Higgins, D. G.; Heringa, J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. *J. Mol. Biol.* **2000**, *302*, 205–17.